Actuate Therapeutics Inc. (ACTU), a clinical-stage biopharmaceutical company, on Tuesday, announced encouraging interim results from its ongoing Phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel (GnP) in patients with metastatic pancreatic ductal adenocarcinoma.
The trial met its primary endpoint, demonstrating a statistically significant improvement in 1-year survival rate and median overall survival compared to GnP alone.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com